Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Septerna (SEPN) Other Non-Current Liabilities (2023 - 2026)

Septerna's quarterly Other Non-Current Liabilities came in at $100000.0 in Q1 2026, up 270.37% year-on-year from $27000.0 in Q1 2025, and up 4900.0% quarter-over-quarter from $2000.0 in Q2 2025.

Septerna has reported Other Non-Current Liabilities for 4 years, with the latest figure at $100000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Other Non-Current Liabilities rose 270.37% year-over-year to $100000.0; the trailing twelve-month figure through Mar 2026 stood at $100000.0 (up 270.37% YoY), and the FY2024 full-year result was $33000.0, down 93.96% from the prior year.
  • Other Non-Current Liabilities for Q1 2026 stood at $100000.0, up from $2000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $546000.0 in Q4 2023, with the low at $2000.0 in Q2 2025.
  • Average Other Non-Current Liabilities over 4 years is $149833.3, with a median of $66500.0 recorded in 2024.
  • Year-over-year, Other Non-Current Liabilities sank 93.96% in 2024 and surged 270.37% in 2026.
  • Tracing SEPN's Other Non-Current Liabilities over 4 years: stood at $546000.0 in 2023, then slumped by 93.96% to $33000.0 in 2024, then plunged by 93.94% to $2000.0 in 2025, then soared by 4900.0% to $100000.0 in 2026.
  • The last three Other Non-Current Liabilities figures came in at $100000.0 (Q1 2026), $2000.0 (Q2 2025), and $27000.0 (Q1 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Septerna 1.34 Bn 1.34 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 100,000.00
Jun 30, 2025 2,000.00
Mar 31, 2025 27,000.00
Dec 31, 2024 33,000.00
Sep 30, 2024 191,000.00
Dec 31, 2023 546,000.00